Darren A. DeWalt, MD, MPH

Articles by Darren A. DeWalt, MD, MPH

Impact of Including Drug Spending in Oncology Alternative Payment Models

ByLuca Maini, PhD,Jacob P. Klimek, PhD,David Johnson, MD, MPH,George M. Holmes, PhD,Darren A. DeWalt, MD, MPH

November 3rd 2023

This study demonstrates a method for understanding the effects of drug spending in the design of alternative payment models.

Leveling the Field: Addressing Health Disparities Through Diabetes Disease Management

ByRichard O. White, MD,Darren A. DeWalt, MD, MPH,Robert M. Malone, PharmD,Chandra Y. Osborn, PhD, MPH,Michael P. Pignone, MD, MPH,Russell L. Rothman, MD, MPP

January 14th 2010

A subanalysis of a successful algorithm-driven primary care–based diabetes disease management program examines the relationships among patient characteristics, labor inputs, and improvement in A1C level.

Labor Characteristics and Program Costs of a Successful Diabetes Disease Management Program

ByRussell L. Rothman, MD, MPP,Stephanie A. So, PhD,John Shin, BS,Robert M. Malone, PharmD,Betsy Bryant, PharmD,Darren A. DeWalt, MD, MPH,Michael P. Pignone, MD, MPH,Robert S. Dittus, MD, MPH

May 1st 2006

Latest Updated Articles

Impact of Including Drug Spending in Oncology Alternative Payment Models
November 3rd 2023
Labor Characteristics and Program Costs of a Successful Diabetes Disease Management Program
May 1st 2006
Leveling the Field: Addressing Health Disparities Through Diabetes Disease Management
January 14th 2010

Darren A. DeWalt, MD, MPH

Articles by Darren A. DeWalt, MD, MPH

Impact of Including Drug Spending in Oncology Alternative Payment Models

Leveling the Field: Addressing Health Disparities Through Diabetes Disease Management

Labor Characteristics and Program Costs of a Successful Diabetes Disease Management Program

Latest Updated Articles

Trending on AJMC

Hans Lee, MD, Discusses “Off-the-Shelf” Solution for Rare Blood Disorder With No Approved Therapies

FDA Approves Another OTC Naloxone Nasal Spray for Opioid Overdose

Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology

United Therapeutics Plans FDA Submission for Inhaled Treprostinil in IPF

5 Questions Dermatology Patients May Have About Newly-Approved Bemotrizinol